Under the pact, Evotec will use its drug discovery technologies for identifying small molecules against the UCB selected targets.
The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.
As per the terms of the agreement, UCB is responsible to pay fixed research funding fee as well as discovery, preclinical and clinical milestones to Evotec.
Additonally, UCB will also pay royalties to Evotec based on net sales of any approved drugs under the collaboration.
Further financial details have not been disclosed.